Steve Kasok is an operationally oriented financial executive with broad life science expertise. He co-founded and served as CFO of Brammer Bio and Gallus Biopharmaceuticals which are both now part of Thermo Fisher Scientific. He previously served on the Boards of Cognate Bioservices and Brammer Bio. His operational responsibilities have included Finance, Business Development, Human Resources, Information Technology and the Legal functions. Kasok’s broader industry experiences included roles as Vice President and Treasurer of Millipore Corporation, CFO of Cabot Supermetals, and Treasurer and Business Development Officer at Haemonetics Corp, and a variety of roles in GE. He earned a BS in Finance from Clarkson University and an MBA from Harvard Business School.
Clare joined EnPlusOne in 2025 as CEO, bringing significant experience as a company builder, deal maker, and drug developer in the biotechnology industry.
Clare was previously a co-founder of Life Edit Therapeutics, a subsidiary of ElevateBio, where she was a member of the executive leadership team and most recently served as Senior Vice President for Corporate Development and Operations. At Life Edit, Clare led the company through several important milestones including developing and closing transformational deals with Moderna and Novo Nordisk, and advancing programs from indication selection through development candidate nomination. Prior to joining Life Edit, Clare worked at Evotec, SCYNEXIS and Novartis.
Clare Holds an MBA from The Fuqua School of Business, Duke University, a PhD in synthetic organic chemistry from the University of Liverpool, and a BSc in Chemistry from the University of Liverpool.
Dan is Co-founder, COO, and Board Director of EnPlusOne Bio. He joined the team while attending business school and was introduced to the scientific co-founders through participation in the Nucleate Program at Harvard. During this experience, Dan became convinced EnPlusOne had the technology and team to tackle the many problems facing RNA synthesis. Upon graduation, Dan was selected as a Blavatnik Fellow in Life Science Entrepreneurship which provided resources and mentorship instrumental in founding EnPlusOne. Working in the cutting-edge space of RNA is well-aligned with his passion for the biotechnology industry and rare diseases. Previously, he worked at Sanofi as a process engineer supporting large scale cGMP manufacturing of enzyme replacement therapies. Most recently, he led the design, construction, and validation of purification operations for a new continuous biomanufacturing facility, awarded the 2020 ISPE Facility of the Year. Dan earned his BS in Chemical Engineering from Northeastern University and an MBA from Harvard Business School.
Jim Weissman is principal of JBW Consulting, where he advises biopharmaceutical companies on business strategy and corporate development. He serves as an independent director for Cerberus Therapeutics, Constructive Bio, and Telesis Bio. Previously, he spent more than a decade at Dicerna Pharmaceuticals, serving as EVP, COO, and CBO. Dicerna, a developer of RNA interference (RNAi) based medicines, was acquired by Novo Nordisk for $3.3 billion in 2021. During his time at Dicerna, the company expanded its GalXC RNAi platform to support nearly 20 development programs and formed six collaborations with Alexion, Alnylam, Boehringer Ingelheim, Lilly, Novo Nordisk, and Roche, generating more than $1 billion in upfront, milestone, and related payments by the time of the acquisition. He also supported the company’s financings, including its 2014 IPO.
Before joining Dicerna, Jim was vice president of business development at MannKind Corporation. He previously held business development and marketing roles at Pfizer in Tokyo and commercial and leadership positions at Pharmacia Biotech across the United States, Sweden, Japan, and the United Kingdom. Jim earned a B.S. in chemistry from Bates College.
Julia partners with bold entrepreneurs building the bio-based future. She is a Managing Partner at Breakout Ventures, investing in early stage companies harnessing the power of cells to build solutions in human health and sustainability.
Julia has spent her career as an investor and operator, navigating the translation of new technologies in life sciences to customer adoption and scale. She has been investing in and building venture-backed, science-driven companies for the last 15 years and has worked with multiple companies from founding through IPO or M&A. Julia began her career as a public investor and research analyst on Wall Street. She is also a Kaufman Fellow. She is a graduate of the University of Virginia, where she studied Finance and Bioethics.
Paxton Major is a Director at Northpond Ventures. He joined Northpond in August 2018 as a member of the investment team, helping lead investments in biopharma R&D tools, precision medicine, and digital health. Paxton is a board director at EnPlusOne, Kytopen, Molecule, QbD Vision, and Teckro. Some of his active and past board observer roles include Elephas, Scitara, Selux Diagnostics, SimBioSys, Syapse, VieCure, Current Health (acquired by BBY), and NanoView (acquired by Unchained Labs). Previously, Paxton was a consultant at Trinity Partners, a life science-focused strategy and management consultancy that advises clients by providing in-depth market, competitor, customer, and financial insights. Paxton earned a B.S. with honors in neurobiology from Brown University.
